ElpasBio

ElpasBio (ElpasBio Holdings) is a clinical-stage biotechnology company specialized in regenerative medicine and allogeneic stem cell therapies. Spun off from AbelZeta Pharma in 2023, the company continues the development of mesenchymal stem cell assets originally established by Cellular Biomedicine Group (CBMG). Its lead product candidate, lotazadromcel (trade name AlloJoin), is an off-the-shelf, human adipose-derived mesenchymal stem cell therapy currently in Phase 3 clinical trials for the treatment of knee osteoarthritis in China. ElpasBio's proprietary haMPC platform aims to provide disease-modifying solutions for degenerative diseases by suppressing inflammation and promoting tissue repair. The company maintains integrated GMP-compliant manufacturing and research facilities in Wuxi and Shanghai to support its clinical pipeline. In early 2026, ElpasBio entered into a strategic commercialization partnership with Fosun Kairos to bring its stem cell therapies to the Greater China market.